BIOCRYST PHARMACEUTICALS

biocryst-pharmaceuticals-logo

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development prog... rams including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.

#SimilarOrganizations #People #Financial #Event #Website #More

BIOCRYST PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Clinical Trials Therapeutics

Founded:
1986-01-01

Address:
Birmingham, Alabama, United States

Country:
United States

Website Url:
http://www.biocryst.com

Total Employee:
101+

Status:
Active

Contact:
9198591314

Email Addresses:
info@biocryst.com

Total Funding:
1.31 B USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag Sitelinks Search Box IPv6


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.


Current Advisors List

kenneth-lee_image

Kenneth Lee Board of Directors @ BioCryst Pharmaceuticals
Board_member

george-abercrombie_image

George Abercrombie Board of Directors @ BioCryst Pharmaceuticals
Board_member

stanley-c-erck_image

Stanley C. Erck Member, Board of Directors @ BioCryst Pharmaceuticals
Board_member
2008-01-01

Current Employees Featured

charles-gayer_image

Charles Gayer
Charles Gayer Chief Commercial Officer @ BioCryst Pharmaceuticals
Chief Commercial Officer
2020-01-01

william-p-sheridan_image

William P. Sheridan
William P. Sheridan SVP & CMO @ BioCryst Pharmaceuticals
SVP & CMO
2014-01-01

jinky-ang-rosselli_image

Jinky Ang Rosselli
Jinky Ang Rosselli Chief Data & Insights Officer @ BioCryst Pharmaceuticals
Chief Data & Insights Officer
2021-11-01

nancy-hutson_image

Nancy Hutson
Nancy Hutson Director @ BioCryst Pharmaceuticals
Director
2011-06-01

jon-p-stonehouse_image

Jon P. Stonehouse
Jon P. Stonehouse President & CEO @ BioCryst Pharmaceuticals
President & CEO
2014-01-01

matthew-toczko_image

Matthew Toczko
Matthew Toczko Sr. Manager, Chemical Development @ BioCryst Pharmaceuticals
Sr. Manager, Chemical Development
2022-02-01

anthony-doyle_image

Anthony Doyle
Anthony Doyle SVP & Chief Financial Officer (CFO) @ BioCryst Pharmaceuticals
SVP & Chief Financial Officer (CFO)
2020-04-01

thomas-r-staab_image

Thomas R. Staab
Thomas R. Staab SVP & CFO @ BioCryst Pharmaceuticals
SVP & CFO
2014-01-01

Founder


not_available_image

Charles Bugg

Stock Details


Company's stock symbol is NASDAQ:BCRX

Acquisitions List

Date Company Article Price
2012-10-18 Presidio Pharmaceuticals Presidio Pharmaceuticals acquired by BioCryst Pharmaceuticals 101 M USD
2010-10-14 Bioanalytical Laboratory Services Bioanalytical Laboratory Services acquired by BioCryst Pharmaceuticals N/A

Investors List

royalty-pharma_image

Royalty Pharma

Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals

ontario-municipal-employees-retirement-system_image

Ontario Municipal Employees Retirement System

Ontario Municipal Employees Retirement System investment in Post-IPO Equity - BioCryst Pharmaceuticals

royalty-pharma_image

Royalty Pharma

Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals

athyrium-capital-management_image

Athyrium Capital Management LP

Athyrium Capital Management LP investment in Post-IPO Debt - BioCryst Pharmaceuticals

midcap-financial_image

MidCap Financial

MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals

centers-for-disease-control-and-prevention_image

Centers for Disease Control and Prevention

Centers for Disease Control and Prevention investment in Grant - BioCryst Pharmaceuticals

midcap-financial_image

MidCap Financial

MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals

national-institutes-of-health_image

National Institutes of Health

National Institutes of Health investment in Post-IPO Equity - BioCryst Pharmaceuticals

national-institute-of-allergy-and-infectious-diseases_image

National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases investment in Grant - BioCryst Pharmaceuticals

Official Site Inspections

http://www.biocryst.com Semrush global rank: 2.09 M Semrush visits lastest month: 9.96 K

  • Host name: 141.193.213.11
  • IP address: 141.193.213.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "BioCryst Pharmaceuticals"

Home | Biocryst®

Welcome! Bienvenue! We are honoured that you are visiting BioCryst Canada. Headquartered in Toronto, we are a focused, dedicated, and passionate team of biopharma professionals with decades of collective experience serving …See details»

BioCryst Pharmaceuticals - Wikipedia

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in …See details»

BioCryst Pharmaceuticals, Inc. Management Team | Org Chart

BioCryst Pharmaceuticals, Inc. employs 634 employees. The BioCryst Pharmaceuticals, Inc. …See details»

BioCryst Pharmaceuticals - Crunchbase Company …

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an …See details»

BioCryst - Our Medicines, Clinical Trials, Congress …

BioCryst Medical AFFAIRS Navigate the Biocryst Medical Affairs Hub with ease Throughout this resource hub you will find up-to-date information on developing and approved BioCryst medicines, including clinical trials, congress …See details»

BioCryst Pharmaceuticals' Leadership Team - The Org

The leadership team at BioCryst Pharmaceuticals has a history of experience in the …See details»

BioCryst | Denmark | Home

BioCryst is a commercial-stage biotech committed to rare diseases. At BioCryst, our structure-guided drug design propels forward the discovery and development of novel, small-molecule, oral drugs for people living with rare diseases. With …See details»

About Us | BioCryst®

Learn about our mission, explore our company history, and meet our leadership team and board of directors.See details»

BioCryst Strengthens Commercial Rare Disease Leadership

Mr. Hodge joins BioCryst from Array Biopharma, where he helped to build the commercial …See details»

What are Mission Vision & Core Values of BioCryst …

4 days ago BioCryst Pharmaceuticals effectively communicates its mission, vision, and core …See details»

Contact Us in Canada | Biocryst®

Grants BioCryst offers funding to support medical grants or external research grants. Please …See details»

Careers - BioCryst®

Interested in joining BioCryst? Discover the values that drive us, meet members of our team, …See details»

Helen Thackray - Chief Research and Development Officer at …

Helen Thackray, MD, serves as the Chief Research and Development Officer at BioCryst …See details»

BioCryst | Canada | Pipeline

BioCryst are passionate about advancing novel therapeutics for patients with rare and serious …See details»

Patient Advocacy | BioCryst®

I’m passionate about patient advocacy and the vital role it plays in our mission at BioCryst.” My …See details»

BioCryst Announces Sale of European ORLADEYO® (berotralstat) …

5 days ago —Neopharmed Gentili will pay BioCryst $250 million upfront for the European …See details»

BioCryst Pharma Sells European Business for Rare Disease Drug in …

4 days ago BioCryst Pharmaceuticals is selling the European rights and assets for its top …See details»

Product Pipeline | BioCryst®

Explore our pipeline of complement-mediated and rare disease therapeutics, and learn about …See details»

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for …

Jun 25, 2025 BioCryst (BCRX) might move higher on growing optimism about its earnings …See details»

Medicines in Canada | Biocryst®

Immediately report any adverse reaction suspected of being due to a BioCryst medication at …See details»

linkstock.net © 2022. All rights reserved